Form4insider filings, from the source

SEC Form 4 · accession 0000899243-18-014494

LEXICON PHARMACEUTICALS, INC. · LXRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Artal Group S.A.
Director · 10% Owner
Artal International S.C.A.
Director · 10% Owner
Westend S.A.
Director · 10% Owner
Invus Public Equities, L.P.
Director · 10% Owner
Invus Advisors, L.L.C.
Director · 10% Owner
Invus, L.P.
Director · 10% Owner
Pascal Minne
Director · 10% Owner
Period of report
May 25, 2018
Accepted (ET)
May 30, 2018 · 8:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062822

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2,F3,F6,F7May 25, 2018P138,700$9.6249A1,688,700ISee Footnotes
Common StockF2,F3,F6,F7May 29, 2018P147,339$9.8441A1,836,039ISee Footnotes
Common StockF2,F3,F6,F7May 30, 2018P147,339$10.3233A1,983,378ISee Footnotes
Common StockF4,F6,F7holding———21,321,961ISee Footnotes
Common StockF5,F6,F7holding———35,402,689ISee Footnotes

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Invus C.V. directly holds 4,321,214 shares of Issuer common stock. None of the Reporting Persons listed in Footnote 6 hereof have any beneficial or pecuniary interest for purposes of Section 16 of the Exchange Act in the shares of Issuer common stock directly held by Invus C.V. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.